DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia

Background Aberrant promoter DNA methylation has been shown to play a role in acute myeloid leukemia (AML) pathophysiology. However, further studies to discuss the prognostic value and the relationship of the epigenetic signatures with defined genomic rearrangements in acute myeloid leukemia are required. Methodology/Principal Findings We carried out high-throughput methylation profiling on 116 de novo AML cases and we validated the significant biomarkers in an independent cohort of 244 AML cases. Methylation signatures were associated with the presence of a specific cytogenetic status. In normal karyotype cases, aberrant methylation of the promoter of DBC1 was validated as a predictor of the disease-free and overall survival. Furthermore, DBC1 expression was significantly silenced in the aberrantly methylated samples. Patients with chromosome rearrangements showed distinct methylation signatures. To establish the role of fusion proteins in the epigenetic profiles, 20 additional samples of human hematopoietic stem/progenitor cells (HSPC) transduced with common fusion genes were studied and compared with patient samples carrying the same rearrangements. The presence of MLL rearrangements in HSPC induced the methylation profile observed in the MLL-positive primary samples. In contrast, fusion genes such as AML1/ETO or CBFB/MYH11 failed to reproduce the epigenetic signature observed in the patients. Conclusions/Significance Our study provides a comprehensive epigenetic profiling of AML, identifies new clinical markers for cases with a normal karyotype, and reveals relevant biological information related to the role of fusion proteins on the methylation signature.

[1]  D. Berry,et al.  DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Jose Cervera,et al.  Epigenetic regulation of the non‐canonical Wnt pathway in acute myeloid leukemia , 2010, Cancer science.

[3]  M. Nelson,et al.  Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. , 2010, Blood.

[4]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[5]  Marina Bibikova,et al.  A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms , 2009, PloS one.

[6]  P. Bolufer,et al.  Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia , 2009, Leukemia.

[7]  R. Spang,et al.  New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. , 2009, Blood.

[8]  C. O'keefe,et al.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.

[9]  Huanming Yang,et al.  Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. , 2009, Cancer research.

[10]  J. Issa,et al.  Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. , 2008, Blood.

[11]  Yi Zheng,et al.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. , 2008, Cancer cell.

[12]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[13]  L. Wolff,et al.  p15Ink4b: dual function in myelopoiesis and inactivation in myeloid disease. , 2008, Blood cells, molecules & diseases.

[14]  C. Hother,et al.  Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms , 2008, Modern Pathology.

[15]  Quinten Waisfisz,et al.  Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia , 2008, Leukemia & lymphoma.

[16]  Ramón Díaz-Uriarte,et al.  SignS: a parallelized, open-source, freely available, web-based tool for gene selection and molecular signatures for survival and censored data , 2008, BMC Bioinformatics.

[17]  Sandya Liyanarachchi,et al.  CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells , 2007, PLoS genetics.

[18]  J. Boultwood,et al.  Gene silencing by DNA methylation in haematological malignancies , 2007, British journal of haematology.

[19]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[20]  Daniel G Tenen,et al.  The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. , 2006, Genes & development.

[21]  M. Wunderlich,et al.  Human CD34 cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability , 2006 .

[22]  F. Prósper,et al.  Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter , 2006, British journal of haematology.

[23]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[24]  J. Herman,et al.  The fundamental role of epigenetics in hematopoietic malignancies. , 2006, Blood reviews.

[25]  S. Fröhling,et al.  Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Spector,et al.  Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Hirohashi,et al.  Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. , 2005, Human molecular genetics.

[28]  M. Tormo,et al.  Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. , 2005, Haematologica.

[29]  T. Graf,et al.  Stepwise Reprogramming of B Cells into Macrophages , 2004, Cell.

[30]  D Bentley,et al.  Highly parallel SNP genotyping. , 2003, Cold Spring Harbor symposia on quantitative biology.

[31]  Javier Benitez,et al.  Cancer Epigenetics and Methylation , 2002, Science.

[32]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[33]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. MacKenzie,et al.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. , 2002, Blood.

[35]  Wendy Kennedy,et al.  Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1 , 2001, Oncogene.

[36]  M. Toyota,et al.  Methylation profiling in acute myeloid leukemia. , 2001, Blood.

[37]  I. Wong,et al.  Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.

[38]  Patricia A. Elder,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1998, Genomics.

[39]  J. Cerhan,et al.  HEMATOLOGIC MALIGNANCIES , 2007, UICC Current Treatment of Cancer.